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ABSTRACT
Anti-NMDA receptor encephalitis (ANMDARE) is a relatively newly discovered autoimmune and inflammatory
disorder affecting the limbic system. It has a clinical course that includes prodromal, psychiatric, unresponsive,
and hyperkinetic stages. These stages are often confused with mental health issues in the medical literature,
but they also share symptoms of various drug intoxication and withdrawal states. Implicit bias in physicians
regarding substance use disorder and patient demographics can impair delivery of care and outcomes in
patients with ANMDARE, especially in a setting with a high prevalence of recreational drug use. When clinical
presentation aligns, this diagnosis should be investigated as soon as possible, even in the case of atypical
presentations or in those with past or current substance use disorder. Early identification and treatment are
essential to good outcomes and minimal sequalae at two years. Therefore, it is essential to consider ANMDARE with the symptom profile regardless of patient age, sex, race, or clinical disorder. Below, the difficulty
in diagnosing ANMDARE is detailed in a 32-year-old white male with a history of methamphetamine, opioid,
benzodiazepine, and marijuana use.
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INTRODUCTION
Anti-NMDA receptor encephalitis (ANMDARE) is a
recently discovered autoimmune and inflammatory neurologic disorder first identified in a cohort of
four women with ovarian teratomas,1,2 but officially
described two years later by Dalmau in 2007.3,4 Predominantly seen in non-Caucasian1,3,5 females (4:1)1,3-8
in their third decade of life,3 it can also
be seen in other mammal species.9
Presentation normally ranges between
19 to 45 years of age4 with a median of
21 years.10 ANMDARE has been highly
associated with underlying tumors,
especially those containing neural
tissue,1 98% of these being ovarian
teratomas.2-6,11-14 Testicular teratomas
and small cell lung cancer can be seen,
especially in males.2,3
ANMDARE often presents with four
stages of characteristic symptoms
(Table 1). A prodromal stage is first
to present with constitutional symptoms.1,3,5,7,9,11,12,15 This period is often
missed, and clinical presentation usually occurs with
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the hallmark psychiatric stage.1,2,4-8,10,11,13-16 The third
stage is an unresponsive stage with catatonia, athetosis, and orofacial dyskinesia.1,3,5,8,9,11-13 Seizures can
occur,2-6,8-16 but tend to be partial rather than generalized1 and rarely advance to status epilepticus.1,2,5
Finally, the hyperkinetic stage occurs with autonomic
instability, arrhythmias, hypotension or hypertension,
central hypoventilation, hyperthermia, and urinary

TABLE 1. Four stages of characteristic
symptons of ANMDARE.
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incontinence.1-5,7-14,16
Due to the psychiatric symptoms, ANMDARE is often
confused with mental health conditions in the current literature. Despite the unresponsiveness, seizures, and autonomic dysfunction, little is mentioned
about confusion with substance use disorders. With
the potential for implicit bias of healthcare workers
towards patients with substance use disorders, patient care can be deleteriously affected.17 Below, the
effect of biases is explored in this case of ANMDARE
in the setting of an area with a high prevalence of
recreational substance use.
CASE PRESENTATION
A 32-year-old Caucasian male with a past medical
history of substance use disorder, anxiety, and bacterial meningitis presented to an outside hospital for
seizure-like activity. Urine drug screen was positive

for methadone, marijuana, and benzodiazepines. The
patient declined further neurologic workup due to
fear of needles and confined spaces and was treated
with levetiracetam (Keppra) empirically.
After discharge, the patient’s family noted him
making random odd comments. He also experienced
auditory hallucination followed by several minutes
of tonic-clonic seizure activity, despite compliance
with levetiracetam. This was followed by a post-ictal
state. In the emergency department, the patient was
alert, oriented to person, and able to follow simple
commands. Neurologic and musculoskeletal examination were unremarkable. Laboratory assessment
revealed a leukocytosis (13 k/mL), low thyroid stimulation hormone (0.323 mIU/L) with normal free t3/t4
(2.86 pg/dL and 1.01 µg/dL), normal creatine phosphokinase (144 U/L), normal metabolic profile, and a
drug screen positive for methadone and marijuana.
Neurology placed him on long-term video monitor-

Differential Diagnosis
Central Nervous System
Demyelinating Disorders
Encephalitis

Meningitis

Acute Disseminated Encephalomyelitis, Neuromyelitis Optica
Autoimmune
GABA, AMPA, LGI1 receptors
PANDAS, Sydenham Chorea, Hashimoto's, Rasmussen,
Encephalitis Lethargica
Autoimmune Synaptic Receptor
Limbic
Bacterial
Viral

Vasculitis, CNS
Drug/Medication Related
Drug Abuse
Drug Withdrawal
MAOI Neurotransmitter Disorder
Neuroleptic Malignant Syndrome
Psychiatric
Childhood Disintegrative Disorder
Kleine-Levin Syndrome
Psychosis
Other
Inborn Errors of Metabolism
TABLE 2. Different Diagnosis for anti-NMDA receptor encephalitis. (GABA = Gamma Aminobutyric
Acid, AMPA = alpha-Amino-3-Hydroxy-5-Methyl-Isoxazoleproionic Acid, LDI1 = Leucine-Rich Glioma-Inactivated 1, PANDAS = Pediatric Autoimmune Neuropsychiatric Disorders Associated with
Streptococcal Infections)1, 2, 5

MARSHALL JOURNAL OF

MEDICINE
™

Expanding Knowledge to Improve Rural Health.

mds.marshall.edu/mjm
© 2021 Marshall Journal of Medicine

Marshall Journal of Medicine
Volume 7 Issue 3

anti-NMDA Receptor
Encephalitis
Prodromal State
Diarrhea
Fatigue
Fever
Headache
Vomiting
Psychotic Stage
Agitation
Delusions
Depression
Hallucinations - auditory
Inattention
Insomnia
Memory loss
Anxiety or paranoia
Unresponsive Stage
Athetosis
Catatonia
Decreased Level of
Seizures
Hyperkinetic Stage
Arrhythmia
Autonomic instability
Central hypoventilation
Hyperthermia
Hypo/hypertension
Hypo/hyperventilation
Urinary incontinence

Alcohol
Use

W/D

Amphetamines

Use

W/D

X

X

Benzodiazepines

Use

W/D

Cannabinoids
Use

W/D

Cocaine
Use

W/D

Hallucinogens
Use

X

X
X
X
X

X

X
X

X

X

X
X
X

X
X

X

X

X
X

X

X
X

X
X
X
X

X

X

X

X
X

X

X

X
X
X

X
X
X

X

X

X

X

X

X
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X

X
X

X
X
X

X

X

X

X
X
X
X

X
X

X
X
X
X

X
X

X

X

X

X

X
X
X
X

X

X

X
X

X
X

X

X

During hospital day 2, the patient was described as
“looking scared... holding stomach... and…spitting”
on LTVM. Electroencephalogram during the event
showed left temporal sharply contoured theta epileptic activity. His valproic acid was increased, and
he underwent MRI, which showed patchy meningeal
signal enhancement in cerebral cortices concerning
for chronic meningitis. Lumbar puncture (LP) was
performed showing pattern concerning for viral
meningitis. He was started on Acyclovir while the PCR
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X
X
X

X
X

X

X
X
X

X
X
X

X
X

TABLE 3. Comparison of stages of anti-NMDA receptor encephalitis with symptoms of different
substance use and withdrawal disorders.

ing (LTVM) and changed his levetiracetam to valproic
acid (Depakene). Workup for infectious etiologies was
initiated, and he was monitored for benzodiazepine
withdrawal.

X
X

X
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W/D

X

X

X

X
X

X
X

X

X

X

Use

X
X

X
X
X

W/D *

Opioids

was pending.
The patient continued to have anxiety, paranoia,
and fluctuating mental status. His symptoms were
magnified during periods of invasive testing, which
required general anesthesia to complete. Suspecting
polysubstance dependence versus delirium, psychiatry started him on ziprasidone (Geodon). On hospital
day 10, he experienced an auditory hallucination
preceding a seizure despite adequate valproic acid
levels. Infectious workup, including herpes PCR, returned negative, as did aerobic, anerobic, and fungal
cerebrospinal fluid cultures. Carbamazepine was
added. A repeat LP was performed for auto-immune
encephalitis, and empiric steroids were initiated.
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X
X

On hospital day 23, anti-NMDA-receptor antibodies were reported positive. IVIG was started as his
steroids were tapered. Paraneoplastic workup was
performed, which found no malignancy; however, a
prosthetic left testicle was discovered, the etiology
of which the patient could not recall. He suffered no
further seizures, though he still dealt with significant
anxiety. He was discharged home on hospital day 28
with family care.
DISCUSSION

of antibody testing, inflammatory markers, imaging
changes, and immunotherapy response, is straightforward.13 ANMDARE can be diagnosed with the triad
of 1) rapid onset of classic symptoms, 2) typical electroencephalogram (EEG) findings of diffuse or local
slowing2,3,5,11,16 and extreme delta brush,3,5,11,16 and 3) a
reasonable exclusion of alternative causes.13
However, cerebrospinal fluid (CSF) and serum IgG
anti-GLuN1 antibodies coupled with the exclusion
of other diagnoses is considered reasonable certainty.8,13 What is difficult, especially in an environment of
significant substance use, is even considering the diagnosis in the first place. The onset of ANMDARE typically presents with psychiatric symptoms, confusing
it with acute intoxication or recreational substance
withdrawal. This requires sequential elimination of
alternate options from the differential (Table 2). Psychiatric diagnoses can be ruled out by the patient’s
progression to the unresponsive and/or hyperkinetic
stages of ANMDARE. Differentiating it from substance use disorder is more complex because of the
wide range of overlapping symptoms (Table 3).

Encephalitis is an inflammatory disorder of the
brain11,13 that develops rapidly17 and has a wide
differential (Table 2). It occurs in 5-10 per 100,000
people yearly, but this is likely an underestimation.3
Encephalitis in the limbic system, which includes
the medial temporal lobes, amygdala, and cingulate
gyrus,11 affects the function of the brain regarding
emotions, anesthesia induced amnesia, aversive
memories, and addictive behavior.4 ANMDARE is
the most common autonomic limbic encephalitis.12 It constitutes up to 40% of viral negative1 and
idiopathic encephalitis2 and also 1% of patients with
encephalitis in the intensive care unit.1 NMDA receptors are located in the forebrain and hippocampus,2,3
as well as the basal ganglia, spinal cord, and cerebellum.5 The receptors are tetramers of glutamine
subunits (2 GluN1 and 2 GluN2/3)1,3,4,7,13 that work as
ligand-gated channels. Through dopamine, serotonin, and glutamate, they play a role in Schizophrenia,2,4 Parkinson’s disease,2,8 Alzheimer’s disease,2,8
and synaptic plasticity,1 the latter of which is important for memory, learning, and cognition.1,8 Expressed
symptoms depend upon affected receptor location.5
While the exact cause has not been clarified,6 pathophysiology follows autoimmune principles as IgG
autoantibodies target the extracellular N-terminal of
the GluN1 subunit.1,8 Crosslinking causes reversible7,8
internalization of both excitatory and inhibitory
receptors,7 which can be seen two hours after in vitro
exposure.1-5,7 Long-term exposure causes excitability
of receptors upon withdrawal.18 The high prevalence
of comorbid tumors, especially those with neurogenic components like ovarian teratomas,2-6,11-14 suggest
a paraneoplastic etiology2 and might supply the
antigenic source for this disease.

Serologic testing lacks the specificity of CSF testing.3,11,13,15 While IgG antibodies of the GluN1 subunit
are useful, there is unclear significance for IgA and
IgM,7,13 as well as autoantibodies for GluN2/3.2,7,12,13
CSF will usually show lymphocytic pleocytosis and
oligoclonal bands.1-3,5,11,13,16 EEG is abnormal in 90%
of ANMDARE cases,1,3,5,11 making it a useful tool to
differentiate it from substance use disorder.12 It most
frequently shows an extreme delta brush pattern or
synchronized delta wave (1-3Hz) superimposed on
fast beta activity (20-30Hz)3,5,11,16 that does not
vary with the circadian rhythm.16 Imaging is largely
unhelpful, as CT is usually normal and MRI is normal
up to 70% of the time. When it is positive, findings
tend to be transient and non-specific,1,2,3,5 with
increased signal on T2-weighted or fluid attenuated inversion recovery in hippocampus, cerebellum,
frontobasal or insular cortex, basal ganglia, brain
stem, and spinal cord.1 Meningeal enhancement,1,10,11
frontotemporal atrophy,3 and periventricular white
matter demyelination1,3,13 can also be observed. PET
scans can reveal occipital lobe hypometabolism.3
Locating an associated tumor with testicular or pelvic
ultrasound may also be helpful in diagnosis.1

The workup for autoimmune encephalitis, consisting

As with other autoimmune pathologies, first line
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treatment of ANMDARE includes decreasing autoantibodies through immunotherapies of steroids, IVIG,
and plasmapheresis.1-8,11,14,15 Resection of a tumor, if
one is identified, improves success of treatment to
80% in combination with first-line immunotherapies.
If those fail, second line treatment is rituximab or cyclophosphamide,1-3,5,6,10,11,14,15 which decreases autoantibody formation by depleting memory B cells, but
is limited due potential side effects.8 Multiple forms
of treatment have proven effective.6,15 Still, long-term
treatment, prolonged hospitalizations, and rehabilitation are common.1 High levels of recovery from ANMDARE, as defined by Modified Rankin Scores, occur
in approximately 80% of patients within 2 years of
disease onset.3,10,11,15 Predictors of good outcomes
include lower severity of symptoms, lower levels of
antibody titers, and early detection of the disorder,
thus leading to early immunotherapy and/or tumor
resection.1,3,5 In fact, not starting treatment within 4
weeks of onset strongly predicts a poor outcome at
1 year.14
Implicit bias in healthcare professionals presents
a potential barrier to early detection of, and thus
better recovery from, ANMDARE. Central Appalachia shares the nation’s prevalence of substance use
disorders, where up to 50% of urban emergency
departments and up to 40% of inpatient admissions
involve alcohol and other substance use disorders.19
Overall, physicians carry negative attitudes towards
patients with substance use disorder,17 and these
attitudes deteriorate throughout training.19 Patients
are labelled as “difficult,” as they are perceived to
repetitively over-utilize healthcare and monopolize
resources.19 These stigmatizing attitudes can affect
healthcare delivery through avoidant behaviors,
poor communication, and misattributing physical
symptoms.17 Medical errors can occur from any of the
32 different identified cognitive biases, but diagnostic inaccuracies predominately are associated with
overconfidence, anchoring effect, information bias,
and availability bias.20
In this case, the patient’s gender decreased the
likelihood of ANMDARE. Furthermore, anchoring on
his substance use disorder delayed diagnosis and
treatment. Alternative diagnoses, including ANMDARE, should be considered when symptoms persist beyond the expected course of intoxication or
withdrawal, or if seizures persist despite therapeutic
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levels of anticonvulsants. Ongoing use of recreational
substances can prolong these times, but this can be
reassessed with repeated drug screening.
CONCLUSION
ANMDARE is a complex medical condition that can
easily be mistaken for psychiatric and substance use
disorders. Physicians should consider all possible differential diagnoses, regardless of patient history and
background, when presented with symptoms that resemble ANMDARE in order to get prompt treatment
and increase the likelihood of full recovery.
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